|Bid||76.60 x 1100|
|Ask||76.62 x 800|
|Day's range||75.65 - 77.79|
|52-week range||23.81 - 78.93|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||30.05|
|Earnings date||03 Nov 2020 - 10 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||93.20|
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the Crain’s Chicago Business 2020 Best Places to Work in Chicago list.
Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) price-to-earnings (or "P/E") ratio of 27.8x might make it...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share. The net proceeds to the Company from this offering are expected to be approximately $798.9 million, after deducting underwriting discounts and other estimated offering expenses payable by the Company. The Company has also granted the underwriters a 30-day option to purchase up to an additional 1,770,000 ordinary shares. The offering is expected to close on or about August 11, 2020, subject to customary closing conditions.